Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Due to the worldwide increasing prevalence of the allergic rhinoconjunctivitis, new
therapeutical strategies are needed. The symptomatic treatment with topical and systemic
antihistamines and corticosteroids are often insufficient. E.coli Nissle 1917 has
immunomodulatory capacities and reveals less side effects. E.coli Nissle 1917 has no sedative
properties and exhibits no hepatotoxic qualities. Thus, E.coli Nissle 1917 represents a new
relevant therapeutical agent.